bluebird bio, Inc. (BLUE)
After hours:
- Business Wire
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.
- Business Wire
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events. LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy for sickle cell disease, with the longest follow-up in the field.
- Business Wire
bluebird bio Announces Receipt of Expected Notice from Nasdaq
SOMERVILLE, Mass., April 26, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports wi
